DE60200317D1 - Formulierung mit gesteuerter Wirkstoffabgabe enthaltend Bupropion-HCI als Wirkstoff - Google Patents

Formulierung mit gesteuerter Wirkstoffabgabe enthaltend Bupropion-HCI als Wirkstoff

Info

Publication number
DE60200317D1
DE60200317D1 DE60200317T DE60200317T DE60200317D1 DE 60200317 D1 DE60200317 D1 DE 60200317D1 DE 60200317 T DE60200317 T DE 60200317T DE 60200317 T DE60200317 T DE 60200317T DE 60200317 D1 DE60200317 D1 DE 60200317D1
Authority
DE
Germany
Prior art keywords
active ingredient
hci
formulation
controlled release
containing bupropion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60200317T
Other languages
English (en)
Other versions
DE60200317T2 (de
Inventor
Roberto Valducci
Tiziano Alighieri
Serozh Avanessian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Valpharma SpA
Original Assignee
Valpharma SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valpharma SpA filed Critical Valpharma SpA
Application granted granted Critical
Publication of DE60200317D1 publication Critical patent/DE60200317D1/de
Publication of DE60200317T2 publication Critical patent/DE60200317T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE60200317T 2001-07-09 2002-06-03 Formulierung mit gesteuerter Wirkstoffabgabe enthaltend Bupropion-HCI als Wirkstoff Expired - Fee Related DE60200317T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT2001MI001457A ITMI20011457A1 (it) 2001-07-09 2001-07-09 Composizione farmaceutica a rilascio modificato contenente bupropionehc1 come sostanza attiva
ITMI20011457 2001-07-09
CA002391691A CA2391691A1 (en) 2001-07-09 2002-06-26 Modified release pharmaceutical composition containing bupropion hci as active substance

Publications (2)

Publication Number Publication Date
DE60200317D1 true DE60200317D1 (de) 2004-05-06
DE60200317T2 DE60200317T2 (de) 2005-02-24

Family

ID=32991642

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60200317T Expired - Fee Related DE60200317T2 (de) 2001-07-09 2002-06-03 Formulierung mit gesteuerter Wirkstoffabgabe enthaltend Bupropion-HCI als Wirkstoff

Country Status (14)

Country Link
US (1) US20030134906A1 (de)
EP (1) EP1275383B1 (de)
JP (1) JP2003048828A (de)
AT (1) ATE262898T1 (de)
AU (1) AU5068202A (de)
BR (1) BR0202759A (de)
CA (1) CA2391691A1 (de)
DE (1) DE60200317T2 (de)
DK (1) DK1275383T3 (de)
ES (1) ES2219602T3 (de)
IL (1) IL149899A0 (de)
IT (1) ITMI20011457A1 (de)
NZ (1) NZ519844A (de)
PT (1) PT1275383E (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN192747B (de) * 2002-04-15 2004-05-15 Ranbaxy Lab Ltd
EP1575565B1 (de) * 2003-08-08 2010-01-06 Biovail Laboratories International Srl Tablette mit modifizierter freisetzung von bupropion hydrochlorid
US8691272B2 (en) * 2005-12-30 2014-04-08 Intelgenx Corp. Multilayer tablet

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4393078A (en) * 1982-03-15 1983-07-12 Burroughs Wellcome Co. Bupropion and ethanol
USRE33994E (en) * 1983-08-16 1992-07-14 Burroughs Wellcome Co. Pharmaceutical delivery system
GB9217295D0 (en) * 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5358970A (en) * 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
WO1998050044A1 (en) * 1997-05-07 1998-11-12 Algos Pharmaceutical Corporation Composition and method combining an antidepressant with an nmda receptor antagonist, for treating neuropathic pain
CA2290624C (en) * 1997-06-06 2006-12-05 John W. Shell Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
US6635280B2 (en) * 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
CA2244097A1 (en) * 1998-08-21 2000-02-21 Bernard Charles Sherman Pharmaceutical composition comprising bupropion hydrochloride and fumaric acid
US6096341A (en) * 1998-10-30 2000-08-01 Pharma Pass Llc Delayed release tablet of bupropion hydrochloride
US6238697B1 (en) * 1998-12-21 2001-05-29 Pharmalogix, Inc. Methods and formulations for making bupropion hydrochloride tablets using direct compression
US6210716B1 (en) * 1999-02-26 2001-04-03 Andrx Pharmaceuticals, Inc. Controlled release bupropion formulation

Also Published As

Publication number Publication date
ATE262898T1 (de) 2004-04-15
DE60200317T2 (de) 2005-02-24
EP1275383A1 (de) 2003-01-15
PT1275383E (pt) 2004-06-30
BR0202759A (pt) 2004-05-11
CA2391691A1 (en) 2003-12-26
ITMI20011457A1 (it) 2003-01-09
EP1275383B1 (de) 2004-03-31
IL149899A0 (en) 2002-11-10
NZ519844A (en) 2003-09-26
JP2003048828A (ja) 2003-02-21
ES2219602T3 (es) 2004-12-01
ITMI20011457A0 (it) 2001-07-09
AU5068202A (en) 2003-01-16
DK1275383T3 (da) 2004-05-24
US20030134906A1 (en) 2003-07-17

Similar Documents

Publication Publication Date Title
NO20054164L (no) Immunoglobulinformulering og fremgangsmåte for fremstilling derav
BR0008590A (pt) Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto
BRPI0412241A (pt) formulação para medicamentos de proteìna sem adição de albumina de soro humano (hsa)
WO2003002136A3 (en) Stable formulation of modified glp-1
ATE302616T1 (de) Oral anzuwendende arzneizusammensetzungen mit gesteuerter wirkstoffabgabe
ZA200307161B (en) Medical aerosol formulations
ATE334663T1 (de) Arzneimittelzusammensetzung mit verzögerter wirkstoffabgabe
PT1283700E (pt) Composicoes farmaceuticas de libertacao prolongada destinadas a administracao por via parental de compostos hidrofilos biologicamente activos
CY1106943T1 (el) Υποδορια εμφυτευματα τα οποια εμφανιζουν περιορισμενη αρχικη αποδεσμευση του ενεργου συστατικου και ακολουθως γραμμικα μεταβαλλομενη εκτεταμενη αποδεσμευση
ATE415943T1 (de) Pharmazeutische zubereitungen enthaltend einen amphoteren emulgator, polyproxylierten cetylalkohol und einen polaren wirkstoff
EP1483277A4 (de) Konjugate biologisch aktiver verbindungen, verfahren zu deren herstellung und anwendung, formulierung und pharmazeutische anwendungen davon
ATE275393T1 (de) Feste dispersionen mit nitrataktiven wirkstoffen
HRP20040849A2 (en) Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof
DE60211464D1 (de) Pharmazeutische formulierungen mit kontrollierter wirkstoff-freigabe enthaltend milchsäure-polymer, sowie deren herstellung
MY151121A (en) Hsa-free stabilized interferon liquid formulations
ATE361060T1 (de) Ionenstärkenunabhängige pharmazeutische formulierung mit verzögerter freisetzung
ATE286736T1 (de) Direktverpressbare matrix zur kontrollierten abgabe von einmaltäglichen dosen von clarithromycin
DE60329968D1 (de) Dosierungsformen enthaltend Thyroidhormone und deren Herstellungsverfahren
EA200901148A1 (ru) Подкожные имплантаты, высвобождающие активные компоненты в течение длительного периода времени
DE60200317D1 (de) Formulierung mit gesteuerter Wirkstoffabgabe enthaltend Bupropion-HCI als Wirkstoff
SE0001916D0 (sv) Novel formulation
WO2002066492A3 (fr) Anticorps specifique de l'adrenomedulline humaine, composition pharmaceutique le contenant, ses applications therapeutiques.
BR0015422A (pt) Formulações de droga de liberação prolongada
TW200727921A (en) Formulation for prolonged release of active ingredients of medicaments
DE60108354D1 (de) 2H-1-Benzopyran-Derivative, Prozesse zu ihrer Herstellung und Pharmazeutische Zusammensetzungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee